liu.seSearch for publications in DiVA
Change search
ReferencesLink to record
Permanent link

Direct link
Allogeneic stem cell transplantation for patients with advanced rhabdomyosarcoma: a retrospective assessment
Technical University of Munich, Germany .
Klinikum Stuttgart, Germany .
Technical University of Munich, Germany .
Technical University of Munich, Germany .
Show others and affiliations
2013 (English)In: British Journal of Cancer, ISSN 0007-0920, E-ISSN 1532-1827, Vol. 109, no 10, 2523-2532 p.Article in journal (Refereed) Published
Abstract [en]

Background: Allogeneic haematopoietic stem cell transplantation (allo-SCT) may provide donor cytotoxic T cell-/NK cell-mediated disease control in patients with rhabdomyosarcoma (RMS). However, little is known about the prevalence of graft-vs-RMS effects and only a few case experiences have been reported. less thanbrgreater than less thanbrgreater thanMethods: We evaluated allo-SCT outcomes of 30 European Group for Blood and Marrow Transplantation (EBMT)-registered patients with advanced RMS regarding toxicity, progression-free survival (PFS) and overall survival (OS) after allo-SCT. Twenty patients were conditioned with reduced intensity and ten with high-dose chemotherapy. Twenty-three patients were transplanted with HLA-matched and seven with HLA-mismatched grafts. Three patients additionally received donor lymphocyte infusions (DLIs). Median follow-up was 9 months. less thanbrgreater than less thanbrgreater thanResults: Three-year OS was 20% (s. e.+/- 8%) with a median survival time of 12 months. Cumulative risk of progression was 67% (s. e.+/- 10%) and 11% (s. e.+/- 6%) for death of complications. Thirteen patients developed acute graft-vs-host disease (GvHD) and five developed chronic GvHD. Eighteen patients died of disease and four of complications. Eight patients survived in complete remission (CR) (median: 44 months). No patients with residual disease before allo-SCT were converted to CR. less thanbrgreater than less thanbrgreater thanConclusion: The use of allo-SCT in patients with advanced RMS is currently experimental. In a subset of patients, it may constitute a valuable approach for consolidating CR, but this needs to be validated in prospective trials.

Place, publisher, year, edition, pages
Cancer Research UK , 2013. Vol. 109, no 10, 2523-2532 p.
Keyword [en]
rhabdomyosarcoma, allogeneic haematopoietic stem cell transplantation, graft-vs-tumour effect, reduced intensity conditioning, myeloablative conditioning, donor lymphocyte infusion
National Category
Medical and Health Sciences
URN: urn:nbn:se:liu:diva-102497DOI: 10.1038/bjc.2013.630ISI: 000327128200003OAI: diva2:678597

Funding Agencies|Wilhelm Sander-Stiftung|2006.109.1|Else Kroner-Fresenius-Stiftung|P31/08//A123/07|BMBF (TranSarNet FK)|01GM087001GM1104B|Deutsche Forschungsgemeinschaft (DFG)|GR3728/2-1|AmGen and Chugai and the Deutsche Kinderkrebsstiftung|DKS 2010.07|

Available from: 2013-12-12 Created: 2013-12-12 Last updated: 2013-12-12

Open Access in DiVA

No full text

Other links

Publisher's full text

Search in DiVA

By author/editor
Antunovic, Petar
By organisation
Department of Clinical and Experimental MedicineFaculty of Health Sciences
In the same journal
British Journal of Cancer
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 34 hits
ReferencesLink to record
Permanent link

Direct link